SCHEMBL2076402

SCHEMBL2076402

O=C1c2ccccc2-c2c(O)cccc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.75
ALDH1A1 P00352 6/20 0.75
MAPK1 P28482 6/20 0.75
TDP1 Q9NUW8 5/20 0.75
MAOA P21397 4/20 0.75
HPGD P15428 4/20 0.75
ALOX15 P16050 4/20 0.75
HSD17B10 Q99714 4/20 0.75
SMN1; SMN2 Q16637 3/20 0.75
LMNA P02545 2/20 0.75
TSHR P16473 2/20 0.75
MAOB P27338 1/20 0.75
HTT P42858 1/20 0.75
MEN1 O00255 8/20 0.64
KMT2A Q03164 8/20 0.64
KDM4E B2RXH2 5/20 0.59
RECQL P46063 5/20 0.59
CYP3A4 P08684 4/20 0.59
MCL1 Q07820 3/20 0.59
BCL2 P10415 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30420953 1.00 MAPT (0.75) MAPTALDH1A1MAPK1TDP1MAOA
SCHEMBL9350943 0.95 MAOA (0.71) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL27634355 0.91 MAOA (0.86) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL30912125 0.91 MAOA (0.86) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL145303 0.91 MAOA (0.86) MAPTALDH1A1MAPK1TDP1MAOA
Anthrarufin SCHEMBL25355428 0.91 MAOA (0.86) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL1893347 0.89 MAOA (0.83) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL27609220 0.89 MAOA (0.83) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL27947853 0.89 MAOA (0.83) MAPTALDH1A1MAPK1TDP1MAOA
1-Hydroxyanthraquinone SCHEMBL28296130 0.89 MAOA (0.83) MAPTALDH1A1MAPK1TDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114231436-B Polycyclic aromatic hydrocarbon degradation strain, screening method and application thereof 上海交通大学 2024-05-17 CN claimed
CN-114231436-A Polycyclic aromatic hydrocarbon degrading strain and screening method and application thereof 上海交通大学 2022-03-25 CN claimed
US-12503480-B2 Cyclic phosphazene compound having oxaphosphorin ring-containing structure FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2025-12-23 US disclosed
US-20240368001-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-11-07 US disclosed
US-11987506-B2 Salt recovery solution and processes of use thereof AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-05-21 US disclosed
CN-114231436-B Polycyclic aromatic hydrocarbon degradation strain, screening method and application thereof 上海交通大学 2024-05-17 CN disclosed
CN-111253525-B Method for treating (methyl) acrylic acid waste water and recycling 四川大学 2024-04-02 CN disclosed
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-20230257284-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2023-08-17 US disclosed
EP-4202013-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE Fushimi Pharmaceutical Co., Ltd. (JP) 2023-06-28 EP disclosed
CN-116282078-A Salt recovery solution and method of using the same 阿克福特斯技术有限公司 2023-06-23 CN disclosed
WO-1999020270-A1 CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 1999-04-29 WO disclosed
WO-1999014217-A1 ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS MERCK & CO., INC. (US) 1999-03-25 WO disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
EP-0375560-B1 ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ELF SANOFI (FR) 1993-05-12 EP disclosed
EP-0443533-A2 Positive photoresist composition FUJI PHOTO FILM CO., LTD. (JP) 1991-08-28 EP disclosed
EP-0375560-A1 Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same ELF SANOFI (FR) 1990-06-27 EP disclosed
US-4447420-A Fluorenone esters of phosphoric and phosphonic acids as insecticides VELSICOL CHEMICAL CORPORATION (US) 1984-05-08 US disclosed
US-3987067-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-3959319-A FREE FLOWING CRYSTALS THE UPJOHN COMPANY (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE PFAS, PHOSPHO1, PAF1 MAPT 3822/4885ALDH1A1 1437/4885MAPK1 1076/4885
US-12503480-B2 Cyclic phosphazene compound having oxaphosphorin ring-containing structure PFAS, PHOSPHO1, PAF1 MAPT 3822/4885ALDH1A1 1437/4885MAPK1 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.